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SUMMARY
Pontocerebellar hypoplasia is a group of heterogeneous neurodevelopmental disor-
ders characterized by reduced volume of the brainstem and cerebellum. We report
two male siblings who presented with early infantile clonic seizures, and then devel-
oped infantile spasms associated with prominent isolated cerebellar hypoplasia/atro-
phy on magnetic resonance imaging (MRI). Using whole exome sequencing
techniques, both were found to be compound heterozygotes for one previously
reported and one novel mutation in the gene encoding mitochondrial arginyl-tRNA
synthetase 2 (RARS2). Mutations in this gene have been classically described in ponto-
cerebellar hypoplasia type six (PCH6), a phenotype characterized by early (often
intractable) seizures, profound developmental delay, and progressive pontocerebellar
atrophy. The electroclinical spectrum of PCH6 is broad and includes a number of sei-
zure types: myoclonic, generalized tonic–clonic, and focal clonic seizures. Our report
expands the characterization of the PCH6 disease spectrum and presents infantile
spasms as an associated electroclinical phenotype.
KEY WORDS: RARS2, Infantile spasms, Whole exome sequencing, Pontocerebellar
hypoplasia type 6.
The early infantile epileptic encephalopathies (EIEEs)
comprise a heterogeneous group of disorders characterized
by early onset seizures, developmental delay/regression,
abnormalities on electroencephalography (EEG), and often
poor neurologic outcome.1 A number of electroclinical syn-
dromes are described, based on age of onset, seizure type,
and electrographic findings. Pontocerebellar hypoplasia
(PCH) is an emerging clinical entity describing a group of
heterogeneous severe developmental disorders affecting
growth and function of the brainstem and cerebellum.
At least 10 forms of PCH are recognized, and many
subtypes have an EIEE phenotype, with different seizure
semiology.2
We describe a family of two affected boys with ponto-
cerebellar hypoplasia type 6 and mutations in RARS2, pre-
senting with infantile spasms. In this report, we delineate
their clinical phenotype, neuroradiologic features, and
molecular genetic findings.
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Methods
Acquisition of clinical cases
Following extensive clinical workup, the reported family
was recruited for research molecular genetics investiga-
tions. Informed written consent was obtained for all partici-
pants. The study was conducted in keeping with the
Declaration of Helsinki.
Molecular genetics
Whole exome sequencing was performed in both affected
individuals. DNA samples were captured using Illumina’s
TruSeq and sequenced on Illumina’s HiSeq2000 using 100
base pair, paired-end reads. We generated 11,845,539,100
and 11,047,647,300 total bases, which leads to mean
on-target coverage of 87.19 and 82.49 per sample. Data
were analyzed according to Genome Analysis Tool Kit’s
Best Practices.3,4 Briefly, this consisted of flagging dupli-
cate reads, realignment around indels, base recalibration,
and variant calling on both samples simultaneously using
the Haplotype Caller tool. Variant qualities were then recal-
ibrated according to Best Practices recommendations for
exomes. Variants that fulfilled the following criteria were
considered for follow-up analyses: (1) variants with a minor
allele frequency < 0.01 in established publicly available
databases (1000 Genomes, ESP6500, and ExAC) and in
~1,800 in-house analyzed exomes; (2) compound heterozy-
gous changes consistent with autosomal recessive inheri-
tance; (3) shared variants on the X chromosome, consistent
with X-linked inheritance; and (4) prediction of putative
pathogenicity based on mutation type, or in silico prediction
of effects on protein function and/or structure, using Poly-
phen (http://genetics.bwh.harvard.edu/pph2/). The identi-
fied RARS2 sequence variations were confirmed by direct
Sanger sequencing using standard methods.
Results
Clinical cases
We describe two affected male siblings born to
nonconsanguineous Caucasian British parents. Family
history was unremarkable.
Patient 1 was delivered at term with a birthweight of
3.57 kg (50th–75th percentile), and head circumference of
35 cm (50th percentile). He presented at 40 h of age with
unexplained hypoglycemia (blood glucose <0.1 mmol/L),
which normalized on feeding. At 5 weeks of age, he mani-
fested clonic seizures, which responded to phenobarbitone.
At 6 months of age, he developed infantile spasms. This
responded partially to high-dose vigabatrin with an approxi-
mate 50% reduction in spasms. From the age of 11 months,
he developed increasingly pharmacoresistant epilepsy, with
tonic and generalized tonic–clonic seizures, refractory to
trial of several anticonvulsants, including sodium valproate,
topiramate, levetiracetam, phenytoin, phenobarbitone, clon-
azepam, and vigabatrin. He required multiple admissions to
the intensive care unit for prolonged seizures. His parents
reported a possible response to pyridoxine therapy, although
this was neither dramatic nor sustained, and therefore not
suggestive of an inborn error of metabolism affecting pyri-
doxal phosphate homeostasis. Introduction of the ketogenic
diet at 2.5 years resulted in a modest reduction in seizure
burden.
He developed a social smile at 5 weeks, but did not
achieve any further developmental milestones. Visual
impairment was apparent clinically by 5 months of age.
Due to progressive bulbar dysfunction, nasogastric feeding
was initiated at 3 years. There was progressive decline in
his head circumference from the 50th percentile at birth, to
the 25th percentile at 22 weeks, to below the 0.4th per-
centile at his last clinical examination. Currently at the age
of 11 years, he has severe neurodisability with peripheral
limb spasticity, scoliosis, and significant seizure burden.
Magnetic resonance imaging (MRI) at 7 months showed a
generalized lack of white matter bulk with a thin corpus cal-
losum, and a small cerebellum, with relative sparing of the
pons (Fig. 1A). EEG studies at 5–6 weeks of age were
normal. At the age of 6–8 months, the EEGwas disorganized
and asynchronous in some parts with frequent bi-hemispheric
generalized bursts of epileptiform activity. This showed
features of a prehypsarrhythmia phase,5 but did not meet
criteria for hypsarrhythmia. Since the age of 11 months,
EEG studies have generally shown asymmetrical frequent
polyrhythmic epileptiform activity maximal in the posterior
regions, and right hemisphere (Fig. 1B). Neurometabolic
investigations were unremarkable, with the exception of an
intermittently raised serum lactate (2.79–4.85 mmol/L,
normal range 0.70–2.10 mmol/L) early in the disease course.
Cerebrospinal fluid (CSF) lactate and pyruvate levels were
within normal limits. CSF and plasma pyridoxal phosphate
levels were normal, as was pyridoxamine 50-phosphate
oxidase (PNPO) mutation analysis. Urine organic acid analy-
sis at 7 months (but not at other times) showed increased
excretion of lactate and citric acid cycle intermediates.
Results of other neurometabolic investigations were within
normal limits. A muscle biopsy carried out at 1 year of age
showed normal histology, electron microscopy, and mito-
chondrial respiratory chain enzyme activity (complex I–IV).
Patient 2 is the younger brother of the index patient. Peri-
natal history was unremarkable. He presented at 8 weeks of
age with clonic seizures, which responded to phenobarbi-
tone. At 5 months, he too developed infantile spasms, which
did not respond to biotin, folinic acid, or pyridoxal phos-
phate, but improved on vigabatrin, with an approximate
50% reduction in seizure frequency. By 16 months, he
developed refractory epilepsy with multiple seizure types,
including myoclonus and tonic spasms. A second trial of
pyridoxal phosphate undertaken at this time reportedly
improved energy levels but did not reduce seizure
frequency.
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Developmentally, his visual behavior was abnormal from
8 weeks of age. Over the years, he developed axial hypoto-
nia and four-limb spasticity. Acquired microcephaly was
also evident. His head circumference fell from the 50th per-
centile at birth to the 2nd percentile by 6 years of age. Full
gastrostomy feeds were required by 3 years of age. Cur-
rently, at the age of 6 years, he continues to have daily sei-
zures despite multiple anticonvulsants and ketogenic diet.
A brain MRI scan (6 months), showed findings similar to
his brother’s (Fig. 1C). EEG at 5 months of age showed fre-
quent bursts of polymorphic high-amplitude focal sharp
delta/theta over both posterior temporal regions with a bias
to the right (Fig. 1D). This evolved to show activity similar
to his brother’s with periods of asynchrony. At 2.5 years of
age, EEG continued to show frequent epileptiform activity
over the posterior temporal and occipital regions. Neonatal
serum lactate levels are not available. A recent serum lactate
level at the age of 6 years was normal (1.6 mmol/L). CSF
lactate and pyruvate levels were normal. CSF pyridoxal
phosphate level was at the lower end of the normal range at
16 nmol/L (normal 14–92 nmol/L). A simultaneous plasma
pyridoxal phosphate was normal at 46 nmol/L (15–
73 nmol/L). Urine alpha aminoadipic semialdehyde was
also normal. CSF glycine was mildly elevated. All other
neurometabolic investigations were normal. He did not have
a muscle biopsy. Clinical microarray testing revealed no
significant pathogenic copy number variants.
Molecular genetic investigation
Two heterozygous variants were identified in RARS2,
independently confirmed by Sanger sequencing and showed
appropriate familial segregation: (1) a 3 bp deletion in exon
7 (NM_020320: c.472_474del, p.K158del; 6:88,239,290)
and (2) a novel missense mutation in exon 10 (NM_020320:
c.848T>A, p.L283Q; 6:88,255,394). The 3 bp deletion has
only been reported in three European Americans in the
heterozygous state in the National Heart Lung and Blood
Institute Exome Sequencing Project (NHLBI ESP) Exome
Variant Server and is therefore very rare. The missense vari-
ant is absent in the 1000 Genomes database, the NHLBI
ESP Exome Variant Server, and dbSNP (v137). PolyPhen-2
predicts the missense mutation to be likely damaging, with a
A
B
C
D
Figure 1.
Radiologic and electrographic features. (A) MRI brain scan for patient 1, 7 months of age: Sagittal T1-weighted and coronal T2-weighted
imaging showing generalized reduction in white matter bulk and marked cerebellar atrophy (yellow arrow) and corpus callosum thinning
(blue arrow) with relative sparing of the pons. (B) Last EEG of patient 1, at 6 years of age, continued to show frequent epileptiform activ-
ity more prevalent over the posterior regions. (C) MRI brain scan of patient 2, age 6 months: Sagittal T1-weighted and coronal T2-
weighted imaging shows marked cerebellar atrophy (yellow arrow), thinning of the corpus callosum (blue arrow), relative sparing of the
pons, and reduction in white matter bulk. (D) EEG of patient 2, age 5 months: EEG showed frequent bursts of polymorphic
high-amplitude focal sharp delta/theta over both posterior temporal regions with a bias to the right.
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score of 1.000, targeting the highly conserved amino acid
L283. All other possible disease-causing mutations identi-
fied in the two subjects that passed our selection criteria
were excluded, leaving RARS2 as the only candidate gene
(Table S1 and Figure S1).
Discussion
Mutations in RARS2 have been reported in patients with
pontocerebellar hypoplasia type 6 (PCH6, OMIM
611523).2,6–12 The gene encodes the mitochondrial aminoa-
cyl-tRNA synthetase (ARS) enzyme, arginyl transfer RNA
synthetase (MIM 611524). ARSs, such as RARS2, attach
amino acids to their cognate tRNA molecules, and play an
important role in mRNA translation, a key process in main-
taining cell integrity.13
Mutations identified in RARS2-PCH, include missense
mutations, deletions, and splice-site variants (Table 1).2,6–12
One RARS2 mutation in our sibship is novel, and the other
previously reported. Glamuzina et al.8 report a patient har-
boring an identical 3 bp deletion (c.472_474del), with the
same predicted functional consequences (loss of lysine158).
Based on homology with the yeast cytoplasmic arginyl-
tRNA synthetase, K158 is located within the active site
domain of the enzyme, and it is postulated that loss of this
amino acid may affect catalytic activity.13
To date, 19 RARS2-PCH cases from 10 families have
been reported (Table 1).2,6–12 Our sibship manifest a num-
ber of clinical features common to those reported, including
infantile-onset of disease, pharmacoresistant epileptic
encephalopathy, severe neurodevelopmental delay,
acquired microcephaly, neonatal hypoglycemia, feeding
difficulties, abnormal visual behavior, and early raised
serum and/or CSF lactate. Patients with RARS2 mutations
manifest multiple different electroclinical phenotypes
including generalized tonic–clonic, focal clonic, and myo-
clonic episodes.2,6–12 Our patients presented with infantile
spasms, which have not been reported in RARS2 PCH6 pre-
viously. However, it is well recognized that the etiology of
infantile spasms is heterogeneous (Table S2 and Supporting
information references).
From a radiologic perspective, RARS2-PCH is associated
with cerebral atrophy and pontocerebellar hypoplasia/atro-
phy. It is postulated that supra-and infratentorial atrophy
may be progressive over time, and pontine involvement
may not be present in the early stages.6,8–10 In both our
patients, MRI, undertaken within the first year of life,
revealed a small cerebellum and generalized reduced white
matter bulk with an abnormal corpus callosum. Further
serial neuroimaging was not possible for medical reasons.
Other radiologic features described in reported patients
include subdural effusions (secondary to cerebral atrophy)
and abnormal myelination. Elevated lactate peak on
MR spectroscopy has also been reported in some
RARS2-mutation–positive patients;9 this investigation was
not undertaken in our patients. It is possible that such
structural changes can contribute to clinical phenotype.
Indeed determinants of the EIEE phenotype are likely to
be multifactorial and governed by the underlying gene
defect at a cellular level, its effect on neuronal networks
within the brain, and any associated brain structural
abnormalities.
In conclusion, we report two patients with RARS2 muta-
tions in the context of severe neurodevelopmental delay, an
intractable seizure disorder and abnormal MRI brain scan.
Our report expands the RARS2 mutational spectrum by
introducing a novel mutation, and extends the range of
electroclinical phenotypes associated with RARS2- PCH6.
Our data suggest RARS2 should be considered in patients
with infantile spasms if other PCH features, such as
imaging findings, are present. Identification of more
RARS2-mutation–positive cases will no doubt provide
further insight into the expanding molecular genotype and
clinical disease phenotype.
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